 Neurobo Pharmaceuticals Inc NASDAQ: NRBO shares are trading higher by 53.74 to 25.92 Thursday morning after the company announced Dong-A has licensed its global exclusive development rights of DA-1241 for type 2 diabetes and non-alcoholic fatty hepatitis and DA-1726 for obesity and non-alcoholic fatty h 